Two staff investigators are proposed. Each has a distinct function and role coordinating unique activities that are not covered by other leadership positions in the Case CCC nor otherwise supported by the CCSG. Jill Barnholtz-Sloan, PhD, an expert in biostatistics and bioinformatics with a special interest in cancer genomics with links to clinical annotation, is spearheading the integration of annotated data sets across the Cancer Center and its consortium sites. She has a unique skill set in overcoming institutional barriers to collaborative efforts especially as it relates to clinical informatics for research. Her role as staff investigator will be to promote such activities across scientific programs, clinical research activities and sites, and to facilitate enhanced collaborative investigations. Yogen Saunthararajah, MD has developed strong collaborative efforts in the areas of drug discovery and drug development through his interest in targeted therapeutics. He is a member of the Hematopoietic Disorders and Developmental Therapeutics Programs where he has successfully developed new drugs that target myeloid malignancy differentiation through demethylation. In his role as staff investigator, he will further coordinate drug discovery and development of investigators across scientific programs and provide the interface from the basic laboratories to clinical investigation. In so doing, he will facilitate multiinvestigator interactions and grant applications. He will partner with Afshin Dowlati, MD, Director of the Center for Cancer Drug Development at CWRU, to provide closer interface with Cleveland Clinic colleagues and scientists.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231|
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376|
|Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237|
|Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
|Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :|
|Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532|
|Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176|
|Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912|
Showing the most recent 10 out of 1227 publications